Provided By PR Newswire
Last update: Oct 30, 2024
LA JOLLA, Calif., Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it has commenced an underwritten public offering of its shares of common stock.
Read more at prnewswire.comNASDAQ:CALC (11/14/2025, 8:00:01 PM)
3
-0.23 (-7.12%)
Find more stocks in the Stock Screener


